Shots:

• The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable- effective cancer drugs to millions of Brazilians
• The 3yrs. research and development collaboration will culminate in protocols for P-I and P-III clinical trials. The companies will take biosimilar pembrolizumab to world markets- following the completion of clinical trials in Brazil
• Pembrolizumab is a biosimilar referencing Merck’s Keytruda- which is used in immunotherapy to treat a variety of cancers including melanoma- lung cancer- head and neck cancer- and stomach cancer

  Ref: PRNewswire | Image: Logos Vector